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Abstract
Objective—To evaluate the safety of co-administering tetanus toxoid, reduced diphtheria toxoid, 
and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse 
events after concomitant and sequential vaccination.
Methods—We conducted a retrospective cohort study of pregnant women aged 14–49 years in 
the Vaccine Safety Datalink from January 1, 2007 to November 15, 2013. We compared medically 
attended acute events (fever, any acute reaction) and adverse birth outcomes (preterm delivery, 
low birth weight, small for gestational age) in women receiving concomitant Tdap and influenza 
vaccination and women receiving sequential vaccination.
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Results—Among 36,844 pregnancies in which Tdap and influenza vaccines were administered, 
the vaccines were administered concomitantly in 8,464 (23%) pregnancies, and sequentially in 
28,380 (77%) pregnancies. Acute adverse events after vaccination were rare. We found no 
statistically significant increased risk of fever or any medically attended acute adverse event in 
pregnant women vaccinated concomitantly compared to sequentially. When analyzing women at 
20 weeks of gestation or greater during periods of influenza vaccine administration, there were no 
differences in preterm delivery, low birth weight or small-for-gestational-age infants between 
women vaccinated concomitantly compared with sequentially in pregnancy.
Conclusion—Concomitant administration of Tdap and influenza vaccines during pregnancy was 
not associated with a higher risk of medically attended adverse acute outcomes or birth outcomes 
compared to sequential vaccination.
Introduction
Inactivated influenza vaccine is recommended at any time during pregnancy to protect 
pregnant women and their infants from the complications of influenza infection (1), and 
more recently, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) 
vaccine has been recommended during pregnancy, with a preference for administration 
between 27–36 weeks of gestation to maximize maternal antibody response and transfer to 
the infant (2). The safety and benefits of influenza vaccination during pregnancy have been 
well studied (3–6). Vaccination during pregnancy decreases morbidity in the pregnant 
women and also protects the infants from disease caused by influenza infection. Recently, a 
few studies have shown that the Tdap vaccine is safe in pregnancy (7–10), and others have 
shown effectiveness in decreasing the burden of pertussis in infants (11, 12).
Studies evaluating the safety of co-administering Tdap and influenza vaccines in non-
pregnant individuals have not found an increased risk of adverse events when compared to 
sequential vaccination (13, 14). Given the likelihood that concomitant vaccination will occur 
in pregnancies that overlap with the influenza season, and the potential for different 
responses to vaccinations in pregnant women compared to non-pregnant individuals (15), 
we evaluated whether there was an increased risk of medically attended acute events or 
adverse birth outcomes when Tdap and influenza vaccines are administered concomitantly 
during pregnancy.
Materials and Methods
We conducted a retrospective cohort study using data from the Vaccine Safety Datalink to 
assess the safety of concomitant Tdap and influenza vaccine administration in pregnancies 
ending in live births by evaluating medically attended acute events and adverse birth 
outcomes in women who received Tdap and influenza vaccines on the same day compared 
to different days (sequentially) in pregnancy.
The Vaccine Safety Datalink is a collaborative project between the Centers for Disease 
Control and Prevention (CDC) and 9 integrated health care organizations with an annual 
birth cohort of approximately 90,000 per year (16). For this study, seven Vaccine Safety 
Datalink sites contributed data: Group Health Cooperative (WA), Kaiser Permanente 
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Northwest (OR) and (WA), Kaiser Permanente Northern California (CA), Southern 
California Kaiser Permanente (CA), HealthPartners (MN), Marshfield Clinic (WI), and 
Kaiser Permanente Colorado (CO).
We identified pregnancies ending in live births between January 1, 2007 and November 15, 
2013 using a validated algorithm (17) used in prior Vaccine Safety Datalink pregnancy 
studies (3, 4). This pregnancy episode algorithm uses claims, administrative, and birth data 
to identify pregnancies and their associated outcomes and dates.
We included pregnant women aged 14–49 years who received Tdap and influenza vaccines 
during pregnancy and had continuous insurance coverage from 6 months prior to pregnancy 
to 6 weeks postpartum with no greater than a 30 day gap in enrollment. We excluded women 
who received any live vaccines in pregnancy, those with multiple gestations, and those with 
non-live birth outcomes, including stillborn, spontaneous abortion, therapeutic abortion, 
trophoblastic disease, and ectopic pregnancy, since we did not access medical records to 
confirm these outcomes and their onset dates. Additionally, we excluded women who 
received more than one tetanus containing vaccine (including multiple Tdap vaccines) in the 
same pregnancy and women who received more than one influenza vaccine (seasonal 
influenza and H1N1 influenza or multiple seasonal influenza vaccines) on different days in 
the same pregnancy, in order to limit our comparisons to women with a single influenza 
vaccination date and a single tetanus vaccination date. For example, a woman who received 
a seasonal influenza vaccine and an H1N1 influenza vaccine on the same day would be 
included in the cohort, but if she received these vaccines on different days, she would be 
excluded. Women may have received multiple vaccinations of the same strain during 
pregnancy in cases where a pregnancy spanned two different influenza vaccination seasons 
(i.e. February and September of same calendar year) or in cases of provider error.
We identified Tdap and influenza vaccinations administered during pregnancy using 
electronic medical record and claims data. We defined a vaccine administered during 
pregnancy as one given from 7 days after the last menstrual period through 7 days before the 
pregnancy end date. We used these cut offs to avoid inadvertently including vaccines that 
might have been given prior to pregnancy or in the post-partum period (18).
We compared baseline characteristics between the two cohorts using chi-squared tests for 
categorical variables and t-test for continuous variables. We used a log binomial regression 
analysis in order to calculate the relative risks for both rare (acute outcomes) and non-rare 
(birth outcomes) events. We identified all covariates and medically attended acute events 
using International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes. We adjusted for differences in Vaccine Safety Datalink site and 
gestational age at Tdap vaccination as a linear covariate when comparing acute events. 
Additionally, we adjusted for maternal age, the presence of a maternal comorbidity (from 6 
months prior to pregnancy through 30 days postpartum), the presence of a pregnancy 
complication, season of delivery, prenatal care utilization (19), and length of enrollment 
prior to pregnancy when comparing birth outcomes. We tested for effect modification by 
gestational age in weeks at Tdap vaccination for each outcome. All analyses were performed 
using Statistical Analysis System (SAS) software, version 9.3 (Cary, North Carolina).
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We compared medically attended acute outcomes (fever, limb pain, limb swelling, cellulitis, 
lymphadenitis, Arthus reaction, allergy, urticaria, and anaphylaxis) between concomitant 
and sequential vaccine recipients in the 0–3 and 0–7 days after Tdap and influenza vaccines. 
Outpatient diagnosis codes on the day of vaccination were excluded, as the diagnosis was 
likely present before the vaccination. We also compared the risk of incident Guillain-Barré 
syndrome occurring 1–42 days after vaccination. The day of vaccination was considered day 
0. For the group of concomitant vaccine recipients, we examined events in three risk 
windows after vaccination (0–3, 0–7, and 1–42 days). For the group of sequentially 
vaccinated women, we examined each of the three windows after both Tdap and influenza 
vaccination dates. The time windows were allowed to overlap in women receiving 
vaccinations on separate days.
We compared the following birth outcomes between the groups: preterm delivery (defined 
as gestational age <37 weeks), low birth weight (LBW, birth weight <2500 grams), and 
small for gestational age (SGA, <10th percentile for gestational age and sex) (20). We had 
initially planned to perform the analysis on the entire cohort; however, based on further 
evaluation examining the seasonal differences in influenza vaccine administration and 
differences in the gestational age at which Tdap vaccine is preferentially administered, we 
limited our analysis of adverse birth outcomes to women vaccinated during periods of peak 
influenza vaccine administration (September through January) and vaccinated at 20 weeks 
of gestation or greater. This allowed us to capture women who had an opportunity to be in 
either cohort, since they would be eligible for concomitant or sequential vaccination. 
Additionally, this would address biases associated with the seasonal differences in birth 
outcomes (21). Finally, we limited our analysis of birth outcomes to women vaccinated prior 
to 37 weeks of gestation, so as to not bias our results towards any protective effect of 
vaccination (22, 23) and to pregnancies with known gestational age and birth weight 
recorded in the electronic health record or linked to the state birth registries.
We performed a priori power calculations and determined that we had 80% or higher power 
to detect relative risks of greater than 2 for all of our birth outcomes, even with the restricted 
cohort. However, our analyses for medically attended acute outcomes, which are rare, were 
underpowered. For this reason, we limited our analysis of acute outcomes to fever and any 
acute event (37,000 and 10,000 pregnancies needed in each cohort respectively to detect a 
relative risk of 2). We considered results to be statistically significant at an alpha error less 
than 0.05 using 2-tailed tests. The study protocol was reviewed and approved by 
Institutional Review Boards at Emory University, CDC, and the 7 Vaccine Safety Datalink 
sites.
Results
During our study period, we identified 633,542 total singleton pregnancies, 443,774 of 
which ended in live births Figure 1). Our final analytic cohorts for the analysis of acute 
events consisted of 8,464 (23%) pregnancies with concomitant Tdap and influenza vaccine 
administration and 28,380 (77%) pregnancies with sequential Tdap and influenza vaccine 
administration. When comparing baseline characteristics, the cohorts were similar in 
maternal age, enrollment in the health care plan prior to pregnancy, prenatal care utilization, 
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comorbidities, and the receipt of other vaccinations during pregnancy. Most comparisons 
were statistically significantly different, but not necessarily clinically relevant, with the 
exception of gestational age at Tdap and influenza vaccination, which was 25 weeks (range 
1–40 weeks) in the women vaccinated on the same day in pregnancy and 27 weeks (range 
1–41 weeks) for Tdap vaccine and 19 weeks (range 1–40 weeks) for influenza vaccine for 
women vaccinated on different days (p <0.001). Of women vaccinated on different days 
during pregnancy, the mean number of days between Tdap and influenza vaccines was 94 
days with a median of 84 days. The study cohort size for birth outcomes was 4,554 (51%) 
pregnancies with concomitant Tdap and influenza vaccine administration and 4,440 (49%) 
with sequential Tdap and influenza vaccine administration. Distribution of baseline 
characteristics were similar to the full cohort (data not shown).
For the entire cohort of 36,844 vaccinated women, Tdap vaccine was most often 
administered later in pregnancy (37% in second trimester, 56% in third trimester), while 
influenza vaccine was administered relatively evenly throughout pregnancy (34% given in 
the first trimester, 34% in the second trimester, 32% in the third trimester). Women 
vaccinated with Tdap and influenza vaccines on different days received influenza vaccine 
earlier in pregnancy, and Tdap vaccine later in pregnancy than women vaccinated on the 
same day in pregnancy. The peak birth year was 2011 for women vaccinated with Tdap and 
influenza vaccines on the same day (36%) and 2013 for women vaccinated on different days 
(44%), likely representing changes to the ACIP recommendations made emphasizing timing 
of Tdap vaccination after 2012. Very few vaccinations occurred in the years 2007–2009 
(<2% of cohort), when Tdap was not routinely recommended during pregnancy.
There were no differences between women receiving Tdap and influenza vaccines 
concomitantly compared to sequentially for medically attended fever and any acute event 
within three and seven days after vaccination Table 1). Overall, acute adverse events after 
vaccination were rare. There were no cases of Arthus reaction or Guillain Barrè Syndrome 
after vaccination. There was no interaction between acute adverse events and gestational age 
at Tdap vaccination (data not shown).
In women who were vaccinated after 20 weeks of gestation during the period of peak 
influenza vaccination administration, there were no differences in the occurrence of preterm 
delivery, LBW, and SGA infants for women receiving concomitant Tdap and influenza 
vaccines compared to women vaccinated sequentially Table 2). There was no interaction 
between adverse birth outcomes and gestational age at time of Tdap vaccination (data not 
shown). As a post-hoc descriptive analysis of the cohort used to evaluate birth outcomes, we 
found that, as expected, most deliveries were occurring in the winter months in both 
concomitantly and sequentially vaccinated women.
Discussion
In our study of pregnant women receiving Tdap and influenza vaccines, we found no 
significant differences in the risk of medically attended acute outcomes between 
concomitant and sequential vaccination. Moreover, we found no differences in preterm 
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delivery, LBW or SGA infants when Tdap and influenza vaccines were co-administered at 
20 weeks of gestation or later during peak influenza vaccine administration.
Our results are similar to randomized studies that have shown no difference in acute events 
after concomitant and sequential Tdap and influenza vaccination in non-pregnant individuals 
(13, 14).. Both prior studies solicited adverse events from patients, while our study relied on 
diagnosis codes from medical visits.
Our study is similar to a Vaccine Safety Datalink study evaluating adverse obstetrical events 
and birth outcomes after Tdap vaccine in pregnancy (10), which included a cohort of 
pregnant women that overlapped with the women evaluated in our study. There are a few 
differences between the two studies. First, the prior study compared Tdap vaccinated women 
to a cohort of unvaccinated women, while we compared two vaccinated cohorts receiving 
both Tdap and influenza vaccine. Additionally, that study adjusted for the exposure to 
influenza vaccine, while all of our women were exposed. Finally, the prior study used a time 
dependent Cox model to evaluate preterm delivery, while we used a log binomial model to 
evaluate preterm delivery. Despite these differences, both studies have similar results, which 
provides additional reassurance of the safety of Tdap and influenza vaccine in pregnancy.
One limitation to our study is that we analyzed only acute events in women who sought 
medical care. However, since pregnant women have frequent medical encounters, especially 
later in pregnancy, minor events may be more likely to be diagnosed and coded in pregnant 
women. The rarity of adverse events in our cohort may also be related to differences in the 
immune response that occur during pregnancy in order to protect the fetus (15). Such 
differences may result in pregnant women being less reactogenic in response to vaccines.
Another limitation is that we did not use chart review to determine if an adverse outcome 
was related to vaccination. However, this non-differential misclassification bias should not 
affect our overall results. We also had two risk windows for women receiving sequential 
vaccination compared to one risk window for women receiving concomitant vaccination, 
which could have made the risk appear higher in the sequentially vaccinated women, 
however, this was not the case. We relied on birth weight and gestational age data from the 
electronic medical record and birth certificates. We believe them to be accurate based on 
prior validation work which has shown a positive predictive value of greater than 90% 
between birth certificate and medical record data at the research sites included in this study 
(24). We were unable to adjust for all potential confounders, including race and ethnicity, 
smoking status, and prior preterm delivery. Finally, we did include long term follow up of 
the infants to monitor for any adverse events.
We observed there are both seasonal differences in influenza vaccine administration and 
differences in the gestational age at which Tdap vaccine is administered in pregnancy. In our 
cohort, influenza vaccine was primarily given during the months of September through 
January, and was administered evenly throughout pregnancy. On the other hand, while Tdap 
vaccine can be given during any stage of pregnancy, the ACIP gives preference to 
vaccination later in pregnancy. In our cohort, Tdap vaccine was generally administered 
during the second and third trimesters. Because of the combination of limited months of 
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influenza vaccine administration and Tdap vaccine administration later in pregnancy, not all 
women were eligible for concomitant vaccination. For this reason, we limited our analysis of 
adverse birth outcomes to women vaccinated at 20 weeks of gestation or later during the 
months of September to January. This was important in order to avoid confounding related 
to seasonality of birth outcomes. Future studies are needed to evaluate non-live birth 
outcomes, such as stillbirth and spontaneous abortions.
We found no differences in medically attended acute events or adverse birth outcomes in 
pregnant women receiving concomitant or sequential vaccination with Tdap and influenza 
vaccines. Our findings should be reassuring to providers and pregnant women, especially for 
women who are later in their pregnancy during months of influenza vaccine administration 
and are most likely to receive concomitant vaccination.
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Pregnant women in the Vaccine Safety Datalink vaccinated with tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines in pregnancy: 2007–
2013. *Singleton pregnancies. †Non-live birth includes stillborn, spontaneous abortion, 
therapeutic abortion, trophoblastic disease, ectopic pregnancy, and unknown outcomes. 
‡Women were given either two seasonal influenza vaccinations or a seasonal influenza and 
H1N1 influenza vaccination on different days in pregnancy.
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